Markets:

Overview

News

Currencies

International

Treasuries

Bayer A G Ord (OP:BAYZF)

45.01 UNCHANGED

Last Price Updated: 11:17 AM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer A G Ord

< Previous 1 2 3 4 Next >

What's Going On With BridgeBio Pharma Stock On Monday? ↗

March 04, 2024

BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.

Via Benzinga

Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial ↗

January 30, 2024

Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer.

Via Benzinga

Topics Lawsuit

Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout ↗

January 29, 2024

"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages.

Via Benzinga

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance ↗

January 11, 2024

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the

Via Benzinga

Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial ↗

January 08, 2024

Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)

Via Benzinga

Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial ↗

January 04, 2024

Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.

Via Benzinga

Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak ↗

December 26, 2023

In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin...

Via Benzinga

Topics Lawsuit

ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US ↗

December 19, 2023

With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience...

Via Benzinga

Topics Climate Change

Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss ↗

December 06, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion ↗

December 04, 2023

The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts

Via Benzinga

Topics Lawsuit

German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks ↗

November 24, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about...

Via Benzinga

Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence ↗

November 20, 2023

Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details ↗

November 20, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF)

Via Benzinga

Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits ↗

November 17, 2023

The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products...

Via Benzinga

Topics Lawsuit

Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss ↗

November 08, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced

Via Benzinga

Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss ↗

November 01, 2023

Bayer AG (OTC: BAYRY) (OTC:

Via Benzinga

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗

August 28, 2023

Reuters

Via Benzinga

German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗

August 28, 2023

Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields...

Via Benzinga

FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗

August 21, 2023

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

Via Benzinga

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗

June 29, 2023

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...

Via Benzinga

Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study ↗

June 28, 2023

Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced

Via Benzinga

US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities ↗

April 04, 2023

Via Benzinga

Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B ↗

March 10, 2023

Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years.

Via Benzinga

Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm ↗

January 18, 2023

Via Benzinga

FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories ↗

January 11, 2023

Reuters

Via Benzinga

Activist Investor Builds Stake In Bayer, Pushes Breakup ↗

January 11, 2023

Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.

Via Benzinga

Ionis Regains Rights To Thrombosis Candidate From Bayer ↗

November 04, 2022

Via Benzinga

Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor ↗

October 05, 2022

Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup...

Via Benzinga

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report ↗

September 14, 2022

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.